BOL-148 / Entheogen - LARVOL DELTA

Ceruvia Lifesciences, Inc. (BIO 2022) - "NYPRG101 (aka BOL-148), a non-hallucinogenic congener of LSD, is set to enter the clinic with a phase 1 SAD trial starting in early Q3 this year. Once this trial is up and running, planning for a Phase 2a trial in migraine will commence, targeting a start date in 1H/2023."

Addiction (Opioid and Alcohol) • CNS Disorders • Migraine • Mood Disorders • Obsessive-Compulsive Disorder • Pain • Psychiatry

HAVN Life Enters into Agreement to Acquire Clinical Stage IP for Development of LSD-Derived API for Cluster Headaches (Issuer Direct) - "HAVN Life Sciences...announce that it has entered into a definitive agreement to acquire clinical stage intellectual property ('IP') from Bolt Therapeutics (the 'Acquisition')....Upon completion of the Acquisition, HAVN Life's research team will explore ways to optimize the patient experience with the neuroprotective agent used in combination with BOL-148, which previously showed a signal of efficacy in a peer reviewed human study."

M&A • CNS Disorders • Migraine • Pain